and Item 7.01, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filing.

Other Events. Progyny, Inc. (the “Company”) announced today that its Board of Directors has approved a share repurchase program to repurchase up to $200 million of its common stock. The program will be funded through available cash balances. Shares may be repurchased through open market repurchases, including through plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, depending on stock price, market conditions and other factors deemed relevant in the Compa…

and Item 7.01, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filing.

and Item 7.01, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filing.

Results of Operations and Financial Condition. On January 12, 2026, Progyny, Inc. (the “Company”) issued a press release to update the Company’s previously issued financial guidance for the three months and year ending December 31, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 1…

President — Michael Sturmer: The President is departing with severance and a consulting agreement, but the company explicitly states it is not naming a successor due to recent leadership enhancements, indicating an orderly restructuring rather than a sudden loss.

and Item 7.01, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filing.

Results of Operations and Financial Condition. On August 7, 2025, Progyny, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…

Results of Operations and Financial Condition On July 8, 2025, the Company issued a press release announcing its entry into the Facility and discussing the Company’s previously issued financial guidance for the three months ended June 30, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Se…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under

Entry into a Material Definitive Agreement. On July 1, 2025, Progyny, Inc. (the “Company”), as borrower, entered into a revolving credit facility (the “Facility”) pursuant to a Credit Agreement dated July 1, 2025 (the “Credit Agreement”) with the Lenders and Issuing Banks party thereto and JPMorgan Chase Bank, N.A., as administrative agent, collateral agent, and swingline lender. Capitalized terms used herein but not defined herein shall have the meanings assigned to such terms in the Credit…

Results of Operations and Financial Condition. On May 8, 2025, Progyny, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as…

Director — Dr. Fred E. Cohen: A director chose not to stand for reelection, which is a routine board turnover event with no stated disagreement.

Results of Operations and Financial Condition. On February 27, 2025, Progyny, Inc. (the “Company”) filed a Current Report on Form 8-K in connection with an issued press release announcing its financial results for the fiscal quarter and year ended December 31, 2024. This Amendment No. 1 to the Current Report on Form 8-K/A amends Item 9.01 (d) Exhibits No. 99.1 to include a corrected range of 61,600 to 64,300 ART cycles expected in 2025 from the previously reported range of 59,350 to 61,850 ap…

Results of Operations and Financial Condition. On February 27, 2025 , Progyny, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter and year ended December 31, 2024. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Excha…

Director — Debra Morris: The filing discloses the appointment of a new independent director to the board and compensation committee, which is a routine governance event rather than an executive departure.

Results of Operations and Financial Condition. On January 13, 2025, Progyny, Inc. (the “Company”) issued a press release to update the Company’s previously issued financial guidance for the three months and year ending December 31, 2024. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 1…

Results of Operations and Financial Condition. On November 12, 2024, Progyny, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2024. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act o…

Results of Operations and Financial Condition. On August 6, 2024, Progyny, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2024. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…

Other Events. Progyny, Inc. (the “ Company ” ) announced today that its Board of Directors has approved a share repurchase program to repurchase up to $100 million of its common stock. This follows the program that was previously announced on February 29, 2024. The program will be funded through available cash balances. Shares may be repurchased through open market repurchases, including through plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, depending…

Results of Operations and Financial Condition. On May 9, 2024, Progyny, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2024. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as…